The Top 5 Biosimilars Articles for the Week of December 2

December 6, 2019

The Center for Biosimilars® recaps the top stories for the week of December 2, 2019.

Transcript

Hi, I’m Laura Joszt for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of December 2, 2019.

Number 5: Writing in a perspective article in The New England Journal of Medicine, a noted critic of high pharmaceutical prices proposed targets for drug price negotiation.

Number 4: A recent study reports that pricing decisions for multiple sclerosis drugs are not the result of needing to recoup specific research and development costs.

Number 3: The FDA released draft guidance for industry on clinical immunogenicity considerations for biosimilar insulins and interchangeable insulins.

Number 2: The European Commission has released a new report that highlights the role that biosimilars and generics will have in the well-being of European healthcare systems in the years ahead.

Number 1: Mylan and Biocon announced that their biosimilar trastuzumab, Ogivri, has become commercially available in the United States.

Finally, last week, our e-newsletter asked which group you think has the greatest responsibility to educate patients about biosimilars and biologics.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit centerforbiosimilars.com.